SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995, that focuses on seed to growth investments in deep technology across health, environmental tech, hardware, robotics, and cross border software, with a particular emphasis on Asia. The company runs accelerator style startup development programs, including HAX and IndieBio, which provide facilities, engineering resources, and lab equipment to help founders accelerate product development, acquire customers, and attract later stage funding. SOSV pursues a limited number of high potential startups, offering extensive hands on support to speed commercialization and scale, and aims to back innovations that improve human and planetary health.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages USD and RMB funds totaling about 9.5 billion in capital and backs early- and growth-stage technology, consumer, and healthcare companies. The firm has backed more than 530 portfolio companies, with over 200 exits via IPOs or M&A, and more than 70 unicorn or super unicorn companies.

OrbiMed is a healthcare-focused investment firm based in New York, founded in 1989, with approximately $5 billion in assets under management. It engages in private equity, venture capital, and growth investments across the global healthcare landscape, spanning biopharmaceuticals, biotechnology, life sciences tools, medical devices, diagnostics, health care services, and digital health. The firm invests across the development spectrum, from startup ventures to mature companies, and pursues opportunities worldwide, including North America, Europe, Asia, Israel and India, leveraging a long-standing specialization in the sector. Through its diversified capital programs, OrbiMed partners with management to advance innovative therapies, tools, and services that address significant medical needs.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization founded in 1982 that supports the region's technology ecosystem. Based in Philadelphia, it acts as a capital provider and catalyst for early-stage and growing technology companies across information technology, health, and physical sciences by offering seed-stage funding and related resources to accelerate commercialization. The organization facilitates university–industry partnerships and regional initiatives that connect scientific research with market opportunities, with the aim of creating jobs and strengthening entrepreneurial communities in Southeastern Pennsylvania. Through its programs and partnerships, it supports adoption of new technologies and helps build a robust regional innovation ecosystem.

New Enterprise Associates is a U.S.-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across stages and geographies, supporting startups from seed to growth. The firm operates globally with investments in the United States, Asia, and Brazil among others, and has a long track record of portfolio IPOs and acquisitions. It has over $19 billion in cumulative committed capital.

High-Tech Gründerfonds is a Germany-based seed and early-stage venture capital firm focused on technology companies in Germany. Based in Bonn with an additional office in Berlin, it operates as a public-private partnership that supports high-tech startups across information technology, software, hardware, life sciences, chemistry and related fields. HTGF provides initial funding and follow-on capital to eligible young companies, often taking minority stakes and participating as lead or co-investor, while offering hands-on guidance from experienced investment managers and startup experts. Since its founding in 2005, the firm has backed numerous startups and facilitated the growth of portfolio companies through multiple funds aimed at early stages. The model combines both public support, involving government and financial institutions, with private investor participation to nurture startups from concept to market.

Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, established in 2013. It targets individual accredited investors who previously had limited access to venture capital by enabling alumni from top entrepreneurial schools to invest together in ventures led by fellow alumni. The firm backs companies with an alumni connection and an institutional lead investor with sector expertise. It offers focused funds that provide accredited investors access to a diversified venture portfolio by type, sector, stage, and geography. The organization engages in seed, early-stage, and late-stage pre-IPO investments across technology, consumer, financial services, health care, life sciences, and other sectors.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. The firm backs entrepreneurs with venture assistance, strategic guidance, and capital, focusing on bold, early-stage technology companies. It invests across sectors including AI, climate and sustainability, enterprise software, consumer technologies, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technologies. Based in Menlo Park, the firm manages several funds to support startups across stages, prioritizing ventures that address large markets and have potential for significant social and economic impact.

HealthTech Capital is a private investor group that funds and mentors healthtech startups at the intersection of healthcare, computing, and mobility. The group aims to foster an ecosystem by connecting clinical providers, venture firms, and other strategic industry players to support healthtech innovation. Founded in 2010 and based in Los Altos Hills, California, it operates as an angel group investing in healthtech startups.

Innovation Works is a Pittsburgh-based venture capital firm established in 1999 that targets seed-stage technology companies in Southwestern Pennsylvania. It provides capital, business guidance, and other resources to high-potential startups and is the region's largest seed-stage investor. The organization also helps manufacturers adopt new technologies and pursues investments in robotics, artificial intelligence, medical devices, retail technologies, and enterprise software.

SFC Capital is a United Kingdom-based venture capital firm founded in 2012 that makes early-stage investments in UK startups, including pre-seed and seed rounds. It backs companies across sectors such as software, technology, e-commerce, consumer, enterprise, green tech, medical technology, and hospitality, providing capital plus strategic guidance to support growth and product development. The firm operates a model that combines an angel network with seed funds to back SEIS- and EIS-qualifying businesses, aiming to offer exposure to a diversified portfolio while delivering hands-on support to portfolio companies.

Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and sells medicines across neuroscience, cardiometabolic diseases, cancer, and immunology. It operates manufacturing and research facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in roughly 135 countries. The portfolio includes Verzenio, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant, reflecting a diversified, science‑driven approach. In addition to human medicines, Lilly conducts research in animal health to treat animal diseases and support agricultural productivity. The company maintains a strong emphasis on research and development to address unmet medical needs and to bring innovative therapies to patients worldwide.

Keiretsu Forum is an international investment community of accredited private equity investors, venture capitalists and corporate/institutional investors. Founded in San Francisco in 2000, it operates as a worldwide network that structures access to high-quality deal flow and investment opportunities through regional chapters across the United States, Europe and Asia. It is described as the world’s largest invitation-only angel investor network, with thousands of investor members who participate in funding opportunities for early- to growth-stage companies in technology, healthcare, energy, consumer products and other sectors. The forum emphasizes collaboration among members and partner resources to support due diligence, syndication and capital deployment, enabling private capital to back high-potential ventures.

Shenzhen Capital Group is a government-backed venture capital firm established by the Shenzhen Government in 1999. It focuses on cultivating national industries and brands, promoting economic transformation, and developing emerging sectors. The firm invests primarily in small to medium-sized enterprises and innovative high-tech companies across start-up, growth, and transformation stages, targeting industries aligned with national policies such as information technology, internet and new media, biopharma, new energy, environmental protection, chemical engineering, new materials, high-end equipment manufacturing, consumer goods, and modern services. Through its portfolio, it aims to build national champions and support industrial upgrading in China, leveraging its capital base to support long-term value creation.

Legend Capital is a Beijing-based venture capital firm and the investment arm of Legend Holdings, established in 2001 to become a leading venture capital manager in China. It manages up to about US$700 million across four funds and focuses on high-growth ventures with operations in China or markets related to China, particularly in early-stage information technology including network applications and services, outsourcing and professional services, and infrastructure components such as IC design, as well as mid-market growth in consumer goods, clean technology, healthcare, equipment manufacturing, and modern services. As an active investor, Legend Capital provides portfolio companies with strategic resources, business development support, and market guidance to help them scale in the Chinese market. Notable investments include Joyo.com, SinoCom, Solarfun Power, Spreadtrum Communications, China Sunshine Paper, and VanceInfo, among others.

Novo Nordisk is a global healthcare company that develops, manufactures, and distributes insulin and other diabetes medicines to treat chronic diseases. It pursues scientific breakthroughs and aims to expand access to its medicines, with the ultimate goal of preventing and curing disease.

IP Group is a London-based venture capital firm that focuses on commercialising intellectual property from research-intensive institutions. It creates value by identifying early-stage IP, developing it into commercially viable opportunities, and forming strategic partnerships to support portfolio companies. The firm provides capital, strategic guidance, and industry insight to science- and technology-based businesses, with emphasis on clean technology, life sciences, and deep tech. With more than twenty years of experience, IP Group supports the growth of science and technology companies from inception toward scale, helping translate research into market-ready products and accelerate their impact.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada, the United States and Europe. The firm invests across the healthcare sector at all stages, with an emphasis on discovery and development of novel therapeutics, and portfolios spanning biotechnology, pharmaceuticals, life sciences, healthcare devices and healthtech. Versant combines deep investment, operating and scientific expertise to support entrepreneurs through hands-on company building. It has backed more than 65 portfolio companies that have achieved acquisitions or IPOs.

Kurma Partners is a Paris-based investment management company focused on funding innovation in healthcare and biotechnology across Europe. Established in 2009, it targets early-stage to development capital for life sciences companies and digital health ventures, spanning healthcare, biotechnology, and related technology sectors. The firm pursues a hands-on approach to support research-driven startups, leveraging connections with research institutes and hospitals to advance therapeutic and medical innovations. Through its activity as a private equity and venture investor, Kurma Partners seeks to back companies throughout their growth trajectory, from initial concept to market readiness, helping them navigate clinical development, regulatory pathways, and commercialization in the European market.

Deerfield Management is a New York-based investment management firm founded in 1994 that focuses on healthcare. It engages in long-term structured investments in both public and private healthcare companies, and operates across investment activities, information services, and philanthropy. It acts as an investment adviser and supports private and public investments across life sciences, medical devices, diagnostics, digital health, and health services.

Panakes Partners is a Milan-based venture capital firm founded in 2015 that makes early-stage investments in life sciences and healthcare companies across Europe and Israel. It supports ambitious teams developing innovative technologies and products in areas such as diagnostic equipment and healthcare technology systems, with the goal of improving patient outcomes and advancing medical solutions.

SV Health Investors is a United States‑headquartered healthcare and life sciences venture capital and growth equity firm. Formerly known as SV Life Sciences, it supports entrepreneurs who create breakthrough companies and treatments across biotech, medical devices, and healthcare services. With offices in Boston, San Francisco and London, the firm has over two billion dollars of capital under management across seven private healthcare funds and more than two decades of activity in the US and Europe.

Parkwalk Advisors is a London-based venture capital firm that focuses on investing in early-stage to growth-stage technology companies, with a particular emphasis on spin-outs derived from UK universities and research institutes. It targets UK-based, often unquoted companies across sectors such as artificial intelligence, big data, life sciences, materials, cleantech, future mobility, medical technology, quantum computing and related fields, and operates with a stage-agnostic approach from seed through later rounds. The firm leverages academic networks, technology transfer channels and venture networks to access deal flow and support portfolio companies. Founded in 2009, it has been aligned with IP Group as part of its corporate structure, reinforcing its focus on intellectual property-backed innovation. The company is headquartered in London, United Kingdom.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Gilde Healthcare, founded in 1982 and based in Utrecht, is a European private equity and venture capital firm focused on healthcare. It operates across Europe and North America, backing growth-oriented companies in medtech, pharmaceuticals, biotechnology, diagnostics, digital health, life sciences, healthcare services, and related enabling technologies. The firm pursues venture capital, growth equity, and buyout investments, often supporting management buyouts and expansion opportunities in early to late stages, including start-ups and more established businesses. Typical investment sizes range from a few million euros up to about €50 million, with a preference for leading roles on the board to drive growth. Gilde Healthcare targets opportunities in Europe and the United States, including Benelux and the DACH region, and seeks exits through IPOs, strategic sales, or other liquidity events. It maintains international reach through activities across its networks and partnerships.

Sand Hill Angels is a Mountain View, California-based angel investor network in Silicon Valley founded in 2000. The group comprises around 60+ technology professionals who collaborate to form and grow startup companies by investing in private technology firms at early stages. Its members focus on technology sectors including clean technology, Internet, information sciences, and life sciences, with activity in areas such as semiconductors, enterprise software, storage, and communications, as well as medical devices, diagnostics, and bioinformatics. Sand Hill Angels typically invest in seed and Series A rounds, and occasionally later-stage bridges, often committing $300K to $500K at a pre-money valuation under $5 million. The network works openly with venture capital funds and other angel groups to support the Bay Area ecosystem.

U.S. Venture Partners (USVP) is a venture capital firm based in Menlo Park, California, founded in 1981. It specializes in early-stage investments across information technology and healthcare, backing companies that develop enterprise software, IT security, consumer internet, mobile, e-commerce, digital health, and IT-enabled healthcare services. The firm partners with entrepreneurs to turn ideas into growth companies and emphasizes sectors such as software, cybersecurity, healthcare tech, and cloud-enabled platforms. Its team comprises former entrepreneurs, technologists, executives, and financial professionals who bring hands-on operational and industry expertise. Over its decades of activity, USVP has supported a broad portfolio across the West Coast and beyond, seeking to build durable businesses with scalable technology and strong markets.

Innova Memphis is a Tennessee-based venture capital firm founded in 2007 with roots in the Memphis Bioworks Foundation. It focuses on pre-seed, seed, and early-stage investments in high-growth biosciences, technology, and agri-tech companies in Tennessee. The firm supports startups from concept to market by providing capital, strategic guidance, and access to industry networks, including connections with established corporations for licensing, buy-outs, or further investments. By combining experienced management, market expertise, and venture capital, Innova Memphis aims to accelerate product development and create viable business units capable of standing independently and collaborating with mature market leaders when appropriate.

RA Capital Management is a Boston-based investment firm that specializes in life sciences and healthcare companies. The firm provides investment management and venture capital services, backing companies developing drugs, medical devices, diagnostics, and biotech tools. Its team combines expertise in biology, chemistry, and medicine with industry and business development experience. RA Capital supports companies across multiple stages, from seed funding to growth financings, including private and public rounds, and often takes board seats and seeks co-investment opportunities. Through its activity, it aims to identify technologies with potential to advance prevention and treatment, genetic testing and personalized medicine, and other patient-focused innovations.

MassVentures is a Massachusetts-based venture capital firm that provides seed and early-stage funding to high-growth startups in the Massachusetts innovation economy, helping concepts move from idea to commercialization. Founded in 1978 as a quasi-public corporation by the Legislature of the Commonwealth, it is governed by an independent board and managed by experienced venture investors. The firm focuses on information technology, healthcare, cybersecurity, e-commerce, mobile, manufacturing, and robotics sectors in Massachusetts and operates accelerator programs to support portfolio companies. MassVentures leverages the state's entrepreneurial ecosystem, educated workforce, and centers of innovation to back early-stage ventures.

Arboretum Ventures is a Michigan-based venture capital firm founded in 2002 and headquartered in Ann Arbor. It invests in healthcare companies across the United States, ranging from seed to growth stages, with a focus on services, medical devices, diagnostics, healthcare information technology, therapeutics, technology-enabled healthcare services, and life science tools. The firm typically targets equity investments of five to fifteen million dollars and concentrates its activity in the Midwest, particularly Michigan.

IDG Capital is a global investment firm that backs technology-focused companies across stages, from early to growth. With a blend of international reach and local market insight, the firm mobilizes resources to help portfolio companies scale in China, Asia, and beyond. It partners with private equity and venture capital fund managers and other investment entities, drawing on a broad base of limited partners including sovereign wealth funds, pension funds, institutions, and family offices. The team combines deep local knowledge with global perspectives to identify opportunities and provide strategic support, governance, and access to networks that accelerate growth. IDG Capital targets software, information technology, consumer and healthcare sectors, among others, and pursues a long-term value strategy through active collaboration with management teams and ecosystem players rather than short-term financing alone.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences from seed to later-stage investments. It backs startups, early-stage companies, corporate spin-offs and occasionally turnaround situations in biopharmaceuticals/biotech, medical devices, and industrial biotechnology. The firm typically takes a lead or cornerstone role, often serving as the first institutional investor in Series A rounds, and actively supports portfolio companies through formation and beyond, including board participation. The firm manages more than €2 billion in life sciences assets.

Verve Ventures is a Switzerland-based venture capital firm and digital investment platform that connects qualified private and institutional investors with startups across Europe. Founded in 2010, it operates a fully digital platform that enables investors to build diversified portfolios with investments starting at 10,000 CHF or EUR. The firm maintains a pan-European network of investors, including family offices and pension funds, and is backed by Zürcher Kantonalbank. An in-house investment team screens thousands of startups annually and selects the top 1% after rigorous due diligence. Verve Ventures sources deals, structures rounds, and facilitates investor participation while also supporting portfolio companies with hiring, client introductions, and access to an expert network. Its portfolio spans sectors such as science and technology, climate energy, robotics, industrial data analytics, advanced manufacturing, digital health, and clean energy infrastructure, and the firm operates with offices in Zurich, Lausanne, Berlin, Paris, and Cambridge as it engages across Europe.

Samsung Electronics is a global technology company based in South Korea that designs, manufactures, and sells a wide range of electronics and device solutions. Its portfolio spans consumer electronics (mobile devices, televisions, home appliances, cameras), information technology products (PCs, peripherals, printers), semiconductors, memory and storage, and display technologies. The company also provides telecommunications infrastructure and related services, and conducts extensive research and development to advance core technologies. With a global footprint across Korea, China, the Americas, Europe, and the Asia Pacific, Samsung Electronics is a leading supplier of smartphones, memory chips, and displays, and it coordinates significant manufacturing and supply chain activities to support its varied product lines.

European Investment Fund (EIF) is a public institution established in 1994 to improve access to finance for Europe's small and medium-sized businesses. It designs and develops venture capital and guarantee instruments to support SMEs and to catalyse private investment, aiming to build a robust European equity ecosystem. EIF engages in venture capital, growth capital, and guarantee operations, backing innovative entrepreneurs primarily in technology and life sciences, as well as across other sectors. Through cornerstone investments and fund participation, EIF seeks to crowd in private investors and stimulate venture activity across Europe. Its equity portfolio has grown substantially, with assets under management exceeding EUR 14 billion, reflecting its broad role in strengthening SME finance and supporting entrepreneurship and growth.

Morningside is a Boston-based investment firm founded in 1986 as a family office for the Chan family. It makes venture capital investments in companies with novel science and technology, with deep expertise in life sciences, digital health, artificial intelligence, materials, and technology. The firm takes a long-term approach to building companies and emphasizes ethical conduct. In addition to its investment activities, Morningside supports charitable initiatives in education, research and healthcare, including collaborations with Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

ShangBay Capital is a California-based venture capital firm founded in 2015 and headquartered in Palo Alto. It targets early-stage healthcare technology companies across the United States, focusing on life sciences, medical devices, biotechnology, and mobile health. The firm seeks opportunities in health tech and related systems to support development and market entry, operating as a registered investment adviser.

Vertex Ventures is a global network of operator-investors and venture capital firms that supports technology and healthcare startups across the United States, China, Israel, India and Southeast Asia. It partners with entrepreneurs by offering hands-on operating experience and broad access to capital, talent, partners and customers to help build global businesses. The firm focuses on early to growth-stage investments in software infrastructure, developer tools, data, security, vertical SaaS, enterprise software and healthcare technologies, drawing on a wide international footprint that includes the US, Israel, Singapore and China. Vertex Ventures emphasizes active portfolio involvement and leverages the broader Vertex network to create value for portfolio companies through strategic guidance and partnerships.

Mitsubishi UFJ Capital is a Tokyo-based venture capital firm established in 1974 with additional offices in Osaka and Nagoya. It focuses on seed, development stage, and startup investments across healthcare, life sciences, biotechnology, information technology, electronics, artificial intelligence, fintech, SaaS, and other high-technology sectors, with an emphasis on the Japanese market and relevance to Japan. The firm also engages in investment syndication for Japanese opportunities.

Aperture Venture Partners is a New York-based venture capital firm that concentrates on healthcare-related investments, including medical devices, biopharmaceuticals, diagnostics, and healthcare IT/services, with an interest in healthy living sectors. It partners with exceptional entrepreneurs to tackle significant problems and create major opportunities, investing nationally with initial commitments typically between $1 million and $5 million. The principals bring decades of leadership in healthcare and investment, and the firm has a track record of activity, having invested more than $1 billion and supported companies with combined revenues exceeding $1 billion.

Vivo Capital is a healthcare-focused investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm operates a multi-strategy platform including growth equity, private equity, venture capital, and public equity, and invests across biopharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and healthcare services. It pursues opportunities globally, including the United States and China, and has invested in more than 290 companies. The team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts, and the firm manages about $5.8 billion in assets.

Hatteras Venture Partners is a Durham, North Carolina-based venture capital and private equity firm founded in 2000 that focuses on funding life sciences and healthcare companies in the United States. Its activities center on biopharmaceuticals, medical devices, diagnostics, healthcare information technology, and related human medicine opportunities, with investments spanning pre-seed to growth stages. The firm typically makes initial investments in the range of half a million to four million dollars and participates in follow-on rounds up to around twenty million, and it operates as a Small Business Investment Company (SBIC). Hatteras also backs adjacent sectors such as software and health services within the Southeast, leveraging an experienced team to support value creation in early-stage biomedical ventures.

Matrix Partners is a San Francisco-based venture capital firm founded in 1977 that backs technology companies from idea through Series A and beyond. The firm focuses on software, AI, B2B, consumer, fintech, health tech, infrastructure, and related sectors, with a global footprint in the United States, India, and China. Its team comprises former founders and operators who work closely with portfolio companies and often join boards to support growth. Matrix Partners has backed a broad slate of successful companies in its decades-long history, including Apple, FedEx, Oculus, Zendesk, HubSpot, Canva, and Postmates, illustrating a pattern of helping developers and builders scale toward IPO or strategic exits. The firm's China arm extends its early-stage and growth investments in the Chinese market, reinforcing its international reach.

Polaris Partners is a Boston-based venture capital firm with offices in Boston and San Francisco that backs technology and life sciences companies across the United States and Europe. Founded in 1996, the firm partners with repeat entrepreneurs to support companies through multiple stages, from inception to growth, with a focus on software, healthcare information technology, digital health, life sciences, biotechnology, pharmaceuticals, genomics, and related sectors. Its investments span the business-to-business and business-to-consumer markets, software as a service, and other technology-enabled solutions, aiming to build durable platform companies and address significant needs in healthcare and technology.

Lumira Ventures is a North American healthcare and life sciences venture capital firm with offices in Toronto, Montreal, Vancouver and Boston. It collaborates with entrepreneurial management teams to build innovative biotherapeutic, medical device, digital health and consumer health companies addressing significant unmet needs and delivering transformation in communities. Since its early years, Lumira Ventures has invested in more than 100 healthcare companies and currently maintains a portfolio of over 30 active investees in Canada and the United States. The firm focuses on biotechnology, biopharmaceuticals, medical devices, digital health and related sectors, providing capital and strategic support, access to networks, and guidance through financings and board participation to maximize technology value.

WI Harper Group is a San Francisco-based venture capital firm with a China-focused footprint, including offices in Beijing and Taipei. Founded in 1993, it invests in startup companies across the United States, Greater China, and the Asia Pacific in sectors such as healthcare, biotechnology, artificial intelligence, robotics, fintech, sustainability, and new media. The firm targets early and expansion-stage opportunities, supporting companies from seed to later rounds and helping bridge U.S. and Greater China markets through cross-border expertise.

Almi Invest is Sweden’s leading early-stage venture capital firm, investing in scalable startups across sustainability, industry, technology, and life sciences. It supports companies from pre-seed to Series A and co-invests with independent private investors to accelerate innovation and long-term success. The firm emphasizes active ownership, providing strategic guidance, board participation, and access to a broad investor network to help startups scale responsibly. Almi Invest operates as part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners, reflecting its public-private model. While focused on Sweden, its portfolio spans diverse sectors, with a mission to drive economic growth and environmental progress by backing entrepreneurs who create tangible impact.

Par Equity is a venture capital and private equity firm backed by Scottish Enterprise, based in Edinburgh with an office in San Francisco. It specializes in early‑stage and growth investments in technology companies, including software, deep tech and digital health, targeting opportunities in Scotland, Northern England and Northern Ireland, with cross‑border expansion between the United Kingdom and the United States. The firm funds proprietary technology and proven products poised for international growth, supporting UK companies expanding to the United States and US entrants seeking a UK presence. Typical investments range from £0.25 million to £2.5 million, with enterprise values up to about £10 million. It also provides angel capital to investee companies and focuses on cross‑border deals to accelerate scale.